Tag Archives: ever

Nov 15, 2020 23.254 minutes to read

Driver Mark Purdon and coach Natalie Rasmussen after winning the NZ Trotting Cup. Photosport

New Zealand’s most successful horse racing stable is being disbanded in news that will shock the industry.

All Stars Racing, the harness racing cage capable of beating all champion coaches Mark Purdon and Natalie Rasmussen, will stop training from 31 December.

The couple remain together as a couple but have decided to take another year of horse training and if and when they choose to return, it will be on a much smaller scale than the large operation they run in Rolleston on the outskirts of Christchurch.

Their state-of-the-art property will remain open but is run by current cage foreman Hayden Cullen and his wife Amanda, with Purdon and Rasmussen happy to help around big carnival time if needed.

But the days of the All Stars engine that dominated harness racing on both sides of the Tasman and were clearly one of the best in the world, are over.

“Time to break,” Purdon told the Herald.

“Between us, Nat and I have been training or working with horses for nearly 70 years,” said 56-year-old Purdon. Rasmussen is 43 years old.

“We want to rest, refresh ourselves and take the time to enjoy life next year.

“And during that break we will take some time to consider what our future will look like.”

Purdon has said he will keep his driving license so he can still drive big race meetings but Rasmussen is still considering whether he will.

Hayden is a good young trainer and we’ve made a commitment to him that at least initially we will ride the horse at the big carnival if the need arises.

“We have told him that we are happy to come to help lead this carnival, but the stables will be his with his wife Amanda and the business will be theirs, obviously not ours.

All Stars Racing will be closed from December 31st and if we return to training full-time I would say it will be on a much smaller scale.

“But it is something we will think about during our year off.”

Purdon will be bringing an elite horse team to Australia for a small campaign at the end of the summer to target the big races there in honor of their owners and the fact that Cullen will be busy setting up his new business.

Purdon and Rasmussen dominated the New Zealand Cup carnival in Addington last week, winning the New Zealand Cup for the sixth time in seven years as well as three other group one races.

Their dominance is unlike any seen in New Zealand races before with home breaking every record in the harness industry.

Purdon was raised to be a champion coach, like his father Roy and brother Barry but since he had his own training in 1995, he has coached a staggering $ 58 million winner in New Zealand alone while he has won most of Australia’s richest few races. time.

Rasmussen joined him as a life and training partner in 2013 and the All Stars operation moved up one notch, with the Australian coach having a relentless work ethic and organizational skills and being a great big racer.

Their superstar pioneering squad is too long to list but was given the title by Lazarus and in the last 12 months they have coached New Zealand and Auckland Cup winners as well as Inter Finals Dominion Pacing and Trotting. Winning normal group races like Oaks and Derby races is so common that they can barely register.

Purdon and Rasmussen informed their staff of their decision to exit the industry full-time this morning and are delighted that many of the owners have not only supported their move but also said they will support Cullen in his new business away from the All Stars property.

But the change in the New Zealand harness racing landscape will be profound.

Stable dominates the betting market and race day and annual sales. For many of their rivals, their departure will create new opportunities and even optimism about their chances of winning at the highest level.

And new faces who win the biggest races won’t hurt New Zealand’s harness racing.

Will Purdon, and even Rasmussen, finally return to full-time training? Maybe.

But will the All Stars Racing behemoth start over and conquer everything in its path? Almost certainly not.

So today’s news is not only the end of an era, but the end of one of the greatest chapters in New Zealand’s racing history.

.

image source

New Zealand

Racing: That copy sends a bold signal to New Zealand’s Cup rivals | Instant News

October 26, 2020 NewsDesk

Sports

Oct 26, 2020 6:46 AM4 minutes to read

It only took 75 years but Pukekohe coach Ray Green had a New Zealand Cup starter, and is now a favorite.

The popular north coach had one of his greatest days in office yesterday when Copy That knocked out his opponents at the Ashburton Flying Stakes just an hour after American Dealer beat the southerners in the heat of the Sires’ Stakes.

The latest win was Green’s 400th training success in New Zealand but the 401 victory was all the more meaningful as Copy That raced through one of the fastest last 400m sections ever recorded in this part of the world.

After working for the lead by a mile from the 2400m stand, Flying Stakes started to leave, Copy That unleashed the final 400m 25.2 seconds, not much slower than any decent race would have raced for the same piece.

That meant the previous NZ Cup favorite Self Assured couldn’t make the ground after sitting in the park while Spankem, who was sitting on the sole clawing his way to third.

The fact that the three favorites settled in the last three places and still dominated suggests one of them should win the $ 540,000 Cup in Addington on November 10, which now Copy That and Self Assured share $ 2.80 of favoritism.

The copy was so fast that, if he could achieve another Cup lead, it would take something better than what we saw yesterday to beat him, with Green not worried about the extra 800m of the Cup even though the Copy was just a four year old who didn’t. ever race for the last ride.

“I don’t think it will bother him, not the way he will stop after this,” said Green.

“You won’t even know he’s been racing, he’s just jogging.

So I think he’s going to tackle the 3200m and I’ll take him to the Cup trials (Addington next week) now just to keep it ticking.

Green has accomplished much in his harness racing career, training and riding horses in Wales and Ireland and has had consistent group-level success with horses such as Sir Lincoln and King Of Swing since taking over as trainer for Lincoln Farms.

But he never even started in the New Zealand Cup, a race every New Zealand rope coach wants to win.

“It’s a tough race to get a horse, let alone win. So I think I’ll be really excited over the next week or two as we get closer,” said Green, who was usually curt.

While the All Stars stables tend to hold a grip on New Zealand Cup favoritism and punters’ hearts, Copy That suggested yesterday if he could take the lead in the Cup he would take an awful lot of run down, especially since this Cup may not have many good enough horses to attack, or hold him to take the lead in this.

So, the draw of the barrier on Wednesday next week will be of great importance, especially as Self Assured looks set to start off on a roll and therefore could give The Copy a great start if the latter draws the front lines.

Green also expects a useful draw and marker run on Cup Day for American Dealers, who beat It’s All About Faith and Krug in the Heat Stakes Sires.

Against the marker, whether leading or trailing, the American dealer can beat the south star but if a horse like Krug, who was brave third after sitting parked yesterday, is in front of him the Sires bet may be over.

However, Green’s brace yesterday revived the Day Cup, which has so dominated the South Island over the past decade.

Another feature of Sunday also goes to another leader in Majestic Man, who used gate speed and high cruising tempo to escape the Flying Mile Trotter at 1: 54.1, just outside of Marcoola’s national mile record.

There’s some good runs behind it but not much that will scare Sundees’ favorite Dominion for what’s ahead in the iconic trot in Addington in two weeks.

.

image source

Brazil

MGC Pharmaceuticals: FIRST HIGH THC PRODUCTS SHIPPED DIRECTLY TO BRAZIL PATIENTS | Instant News

October 12, 2020 NewsDesk

12 October 2020 ASX Code: MXC

MGC Pharma shipped the first high THC formulation direct to

patients in Brazil through the ONIX online platform

Main Highlights:

MGC Pharma completes initial delivery of its Mercury Pharma line, which includes high THC products, direct to patients in Brazil through a supply and distribution agreement with ONIX
A major operational and commercial achievement as MGC Pharma is now the first company globally to ever supply high THC formulations directly to patients in Brazil under the country’s Compassionate Use Program.
Brazil is a market of strategic importance with a population of over 210 million1 people and pharmaceutical market value of ~ A $ 24 billion1 year
Potential to immediately develop new sales of materials and cash flow channels – new patients registering daily in Brazil for MGC Pharma products within weeks of first successful delivery
ONIX is actively recruiting doctors in Brazil and aims to have more than 1,000 doctors with the ability to prescribe cannabinoid products with mid-2021 – significantly broadens the market opportunities for MGC Pharma to supply its formulations

MGC Pharmaceuticals Ltd (ASX: MXC, ‘MGC Pharma’ or ‘Company’), a European based biopharma company that specializes in production and development phytocannabinoid derivativespharmaceuticals, is pleased to announce that it has completed the first shipment of its Pharmaceutical Mercury line which includes a high THC ratio product direct to patients in Brazil through binding supply and distribution agreements with Based in BrazilONIX Empreendimentos e Participações (‘ONIX’), (see ASX release March 3, 2020).

In a major operational milestone, MGC Pharma has become the first company globally to deliver high THC formulations directly to a patient’s door in Brazil, without the need to visit a pharmacy.

MGC Pharma has delivered Mercury Pharma (MP) branded products directly to patients according to the Brazilian Compassion Use Program after receiving the patient prescription given by the ONIX referral doctor. ONIX currently has more than 100 referral doctors in Brazil who can prescribe cannabinoid products under its Compassion Use Program and aims to have more than 300 referral doctors by the end of calendar 2020 and more than 1,000 by mid-2021. A complete line of Mercury Pharmaceuticals is now available. in Brazil which, based on the years experience of the Company’s medical team, covers a product range from pure CBD (MP100) through different ratios (1:30, 1: 1, 7: 1, 15: 1) to pure THC product MP252.

Brazil – Access to Large Target Markets Underway for MGC Pharma

The existing pharmaceutical drug market in Brazil represents a geography of strategic importance for MGC Pharmacy as Brazil has a population of more than 210 million people1. The National Health Expenditure in Brazil is estimated at A $ 267b1 with total expenditures on drugs estimated at A $ 24 billion1 every year. According to Interfarma (Pharmaceutical Research Industry Association), the Brazilian pharmaceutical market is expected to grow from A $ 59.9 billion in 2019 to A $ 66 billion in 2023.3 , through sales of approximately 238 million units3.

–

In addition, there are 10,000 patients in Brazil who are currently registered with the Brazilian local authority, ANVISA, to receive cannabinoid products directly who are suffering from various medical conditions. Only 350 doctors out of more than 500,000 doctors across Brazil are currently authorized to prescribe cannabinoid products. This is expected to change due to the number of initiatives used by ONIX.

ONIX

ONIX is a company based in Brazil that helps companies doing business in the region. It develops its business under the ONIXCANN brand and is a well-established distributor of phytocannabinoid-based products in Brazil that connects doctors and patients. ONIXCANN has an innovative digital and telemedicine platform called CANTERAMED which connects potential patients with relevant medical professionals. CANTERAMED is a complete digital wellness platform that facilitates safe and legal access to phytocannabinoid products and to guide doctors and patients about available treatments.

ONIX has established a partnership with one of the major Universities in Brazil, Anima Educação, and has developed a post-graduation course consisting of 12 nano degree courses of 30 hours each designed to train experienced doctors on CBD and THC products and authorize them to prescribe cannabinoid products.

ONIX has launched the second generation of CANTERAMED platform to help doctors better serve their patients. The CANTERAMED platform has facilitated doctors’ practice with its protocol for using MGC Pharma products and registering treatment results. CANTERAMED includes a telemedicine platform that connects patients with trained doctors to prescribe MGC Pharma products.

ONIX is currently also visiting doctors with a traditional pharmaceutical model who educates doctors about products and aims to have more than 1,000 doctors with the ability to prescribe cannabinoid products to patients by mid-2021.

This initiative is expected to continue to drive market awareness and penetration of cannabinoid products for eligible patients in Brazil.

Roby Zomer, Co-founder and Managing Director of MGC Pharma, comments: “I am very pleased to announce that we have successfully shipped our Mercury Pharma THC product range to Brazil. This is a great achievement as no other company has delivered high THC formulations directly to patients in Brazil before. We have worked closely with our Brazilian partner ONIX and remain confident that Brazil will become a very large strategic and commercially important region for us in the future. Feedback to date from patients in Brazil has been very positive and we see a rapidly increasing demand for our Mercury Pharmaceutical products. “

Marcelo Galvão, Founder of ONIX, comments: “We are very pleased to announce this. It has always been an important part of our strategy to bring high THC products to Brazil. There are more than 30,000 patients currently using homemade oils in Brazil and these patients are in desperate need of a quality product as we do now. take it with the Mercury Pharma Line. ”

–Ends–

Authorized for release by the Board, for more information please contact:

PR / IR advisor – Media & Capital Partners	MGC Pharmaceuticals Ltd.
Melissa Hamilton (PR) +61 417 750274	Roby Summer
Rod Hinchcliffe (IR) +61412277377	CEO & Managing Director
[email protected]	+61 8 6382 3390
[email protected]	[email protected]

–

About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC) is a European-based bio-pharmaceutical company that develops and supplies affordable standard phytocannabinoid-derived medicines to patients globally. The Company’s founders are key figures in the global medical cannabis industry and its core business strategy is to develop and supply high quality phytocannabinoid-derived pharmaceuticals for the growing demand in the medical market in Europe, North America and Australasia. MGC Pharma has a strong product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the path of development.

Using the ‘Nature to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academics to optimize the cultivation and development of targeted phytocannabinoid-derived medicinal products prior to production in the Company’s EU-GMP Certified manufacturing facilities.

MGC Pharma has a number of research collaborations with world-renowned academic institutions, and includes recent research highlighting the positive impact of using a specific phytocannabinoid formulation developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and thus far therapeutically resistant primary brain tumor.

MGC Pharma has a growing patient base in Australia, UK, Brazil and Ireland and has a global distribution footprint through an extensive network of commercial partners which means it is ready to supply the global market.

–

This is an excerpt from the original content. To continue reading, access the original document here.

Rejection

MGC Pharmaceuticals Ltd. publish this content on 11 October 2020 and take full responsibility for the information contained therein. Distributed by the Public, unedited and unaltered, at October 11 2020 21:54:08 UTC

.

image source